A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 As Single-Agent And Combination Therapy In Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Aaron Scott
Sponsor
Exelixis Pharmaceuticals, Incorporated
Unit
Cancer Center Division